For Immediate Release:

IRONSHORE PHARMACEUTICALS TO PRESENT DATA AT THE 6TH WORLD CONGRESS ON ADHD

George Town, Cayman Islands, April 19, 2017—Ironshore Pharmaceuticals & Development, Inc. ("Ironshore"), a wholly owned subsidiary of Highland Therapeutics Inc., today announced that it will be presenting clinical data for its investigational drug candidate HLD200 (delayed-release and extended-release methylphenidate), as well as rating-scale validation work at the 6th World Congress on ADHD (Attention-Deficit / Hyperactivity Disorder), being held in Vancouver, British Columbia from April 20-23, 2017.

“We are delighted to be sharing pivotal trial data and validation work we have conducted in support of two important functional rating scales: the Before School Functioning Questionnaire, or BSFQ, and the Parent Rating of Evening and Morning Behavior – Revised, or PREMB-R, at the World Congress on ADHD,” said Dr. Randy Sallee, Chief Medical Officer. “Our caregiver survey data, which will also be shared at the conference, support the fact that significant unmet medical needs exist in the treatment of ADHD. Ironshore invites all healthcare professionals attending the World Congress on ADHD to visit with us to learn more about the exciting work we are doing.”

Details of Ironshore’s poster sessions are below:

Guided Poster Tour Session P-16: Pharmacological treatment children and adolescents I

Friday, April 21, 2017, 2:30pm to 4pm PDT

Poster #: 010

Efficacy and safety of HLD200, a novel delayed-release and extended-release methylphenidate formulation, in children with Attention-Deficit/Hyperactivity Disorder: Results from a pivotal phase 3 trial

Poster #: 011

Dose proportionality and effect of food on the pharmacokinetics of HLD200, a novel delayed-release and extended-release methylphenidate formulation in healthy adults
Guided Poster Tour Session P-19: Quality of life / Caregiver burden I
Friday, April 21, 2017, 2:30pm to 4pm PDT

**Poster #: 006**
Impact on the family unit of early morning functional impairments in stimulant-treated children and adolescents with Attention-Deficit/Hyperactivity Disorder

Guided Poster Tour Session P-05: Diagnosis I
Friday, April 21, 2017, 2:30pm to 4pm PDT

**Poster #: 007**
Parent ratings on the before school functioning questionnaire (BSFQ) in youths with and without a history of ADHD: Results from a normative survey

**Poster #: 006**
Normative survey data for the parent rating of evening and morning behaviour scale, revised (PREMB-R) in youths with and without a history of ADHD

Specific information about the data contained in the posters is embargoed until the start of the meeting.

About Ironshore Pharmaceuticals & Development, Inc.
Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Highland Therapeutics Inc., is a pharmaceutical company that is leveraging its proprietary technology, DELEXIS®, to optimize the delivery of previously approved drug products.
Highland Therapeutics Inc. is a client of MaRS Discovery District’s Health Venture Services group, which provides advisory services, connections to talent, customer & capital networks, and market intelligence to high-impact, Ontario-based life sciences ventures, helping them commercialize their ideas and build globally competitive companies.

For further information, please contact:
Nelson F. Isabel  
Chief Financial Officer  
(345) 749-8170

Forward-Looking Statements
This press release contains forward-looking information, which reflects Ironshore’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Ironshore’s control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by
applicable law, Ironshore assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.